VDYNE Receives FDA Approval for Pivotal Trial of Tricuspid Valve Replacement System
VDYNE, Inc., a medical device company based in Maple Grove, Minnesota, has received approval from the U.S. Food & Drug Administration (FDA) for an investigational device exemption (IDE) to initiate a pivotal clinical trial. This trial will evaluate the safety and effectiveness of VDYNE's Transcatheter Tricuspid Valve Replacement (TTVR) system in patients with severe tricuspid regurgitation (TR). The IDE approval marks a significant milestone for VDYNE, allowing the company to begin a U.S. pivotal study at leading clinical centers. The TTVR system is designed to provide a minimally invasive solution tailored to the complexities of tricuspid valve anatomy and disease. Since its first use in humans in November 2023, the system has been utilized globally in clinical studies and compassionate use cases, offering insights into procedural performance and clinical outcomes. 
